Clinical Trials

34 enrolled 11 charts

Prostatic Neoplasms

NCT07047118 2026-04-21

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

138 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT00951535 2026-04-17

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

251 enrolled

Prostatic Neoplasms

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06451614 2026-04-16

HYDROSPACE

230 enrolled

Prostatic Neoplasms

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT04215029 2026-04-15

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

6 enrolled

Prostatic Neoplasms

NCT04396808 2026-04-15

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

805 enrolled

Prostatic Neoplasms

NCT04905069 2026-04-15

SABRE

500 enrolled

Phase EARLY_PHASE1 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT05047965 2026-04-15

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT05055843 2026-04-15

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

33 enrolled

Prostatic Neoplasms

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT05828082 2026-04-14

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

20 enrolled

Prostatic Neoplasms

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

8 enrolled

Prostatic Neoplasms

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

DermatologicGenitourinary

62 enrolled

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT01946204 2026-04-13

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

146 enrolled

Prostatic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

90 enrolled 19 charts

Prostatic Neoplasms

NCT03523442 2026-04-13

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Prostatic Neoplasms

NCT03767244 2026-04-13

PROTEUS

2,517 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-04-13

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Prostatic Neoplasms

NCT04557059 2026-04-13

PRIMORDIUM

693 enrolled

Prostatic Neoplasms

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04644770 2026-04-13

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-04-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT04842890 2026-04-13

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

61 enrolled

Prostatic Neoplasms

NCT04898634 2026-04-13

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

216 enrolled

Prostatic Neoplasms

NCT05683691 2026-04-13

VAPOR 2

400 enrolled

Prostatic Neoplasms

NCT05849298 2026-04-13

PSMACare

49 enrolled

Prostatic Neoplasms

NCT06238479 2026-04-13

EXCEED